Cavay Ip

Principal

Cavay Ip helps life sciences clients solve complex challenges for therapies in different lifecycle stages, from pipeline to launch and maturity. His recent experience includes developing launch pricing and market access strategies, global market opportunity assessments (US, EU, and Asia Pacific), authorized biosimilar launch and competitor biosimilar readiness strategies, and value-focused programs and services. He has supported clients across several therapeutic areas, including cardiology, gastroenterology, endocrinology, and oncology.

Mr. Ip also has extensive experience in financial analysis and valuation assessments. He has conducted valuations and solvency analyses for distressed firms and analyzed the financial performance of enterprises as well as specific assets and intellectual property, in both business consulting and commercial/antitrust litigation contexts. In addition to the life sciences industry, he has significant experience supporting clients in the technology, energy (nuclear and oil and gas), hospitals, airline, retail and consumer products, and pulp and paper industries.

Selected Engagements

  • 01
    Kowa Co. Ltd. and Livalo ANDA challenge
    Kowa sought a permanent injunction restraining and enjoining Amneal Pharmaceuticals, LLC (Amneal) and Apotex Inc. (Apotex) from infringing on valid Livalo®...
    View engagement
  • 02
    CRA evaluates commercial efforts to develop a MS drug with respect contractual obligations following merger
    CRA assessed commercial efforts to develop and commercialize a MS drug with respect to obligations stemming from the acquisition of Genzyme Corporation by...
    View engagement
  • 03
    Dr. Gregory K. Bell opines on commercials success of cholesterol drug
    Kowa sought a permanent injunction restraining and enjoining Amneal Pharmaceuticals, LLC and Apotex Inc. from infringing on valid Livalo® patents through the...
    View engagement

Credentials